grow sale market share margin
outperform strong organ growth incorpor higher
margin increas sale adj ep
averag also roll dcf target price goe
see bullish invest case call consensu
underestim organ growth trend potenti room
margin progress mid-term
invest overview underli sale growth y/i
consensu broad base geograph franchis
translat substanti market share gain on-going growth
initi apic taper blt implant drive valu implant clear
align us digit dentistri deliv even elev
expect growth initi come manag
aggress push reach brazil china europ attract
clear-align market combin roll-out premium implant
offer compel growth case view longer term see
upsid straumann push digit consum expans
untap market opportun prevent dental care final
bolt-on activ
catalyst risk cs sponsor investor dinner cfo peter hackel
id march sale april risk stem unexpect
valuat valu straumann per share use dcf model
assum averag sale growth adj ebit margin
tradit multipl stock trade forward price-to-earnings
major discount clear align leader align
valuat metric
price month
price rel chart measur perform
swiss market ind close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
straumann hold ag swiss parent compani
straumann group activ field implant restor
dentistri oral tissu regener product servic
avail countri
price feb rate outperform target price analyst christoph gretler
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
scenario assum straumann gain
signific market share orthodont space gener
underli sale growth around ten year period
assumpt get blue sky scenario
grey scenario assum straumann
maintain histori market share gain dental implant
growth forward price-to-earnings multipl converg industri averag
price-to-earnings around mid term get us grey sky
valuat round
price rel chart measur perform swiss market
ind close
spot exchang rate
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
straumann histor larg market share parallel wall premium implant
market segment sinc launch apic taper implant blt implant straumann
gain market segment repres overal
market expect straumann fulli roll-out last element strategi
expand address market fulli taper implant design strong
initi stabil bone class expect compani gain market share
premium implant segment
figur market share taper non-premium market segment
sinc acquisit neodent straumann expand market
share non-premium implant market today command market share
outsid brazil accord estim well market share premium
market compani focus expand emerg market see non-
premium product franchis grow compani averag
estim straumann gener alreadi sale clear align
thereof sale us see substanti opportun internation
busi compani build domest manufactur capabl brazil
plan launch product rang europ market still
penetr vs us penetr rate henc major potenti
straumann think compani capit exist relationship gener
practition compani test product sever market alreadi plan
roll product broadli go forward china compani recent
announc exclus collabor local partner zhengli fulli approv
solut market alreadi henc posit straumann well larg
market clearcorrect solut approv
digit penetr dental offic still low advanc us market
gener practition use intra-or scanners/chairsid mill equip
far restor busi straumann mainli concentr europ japan
brazil go forward manag focus expand us non-japan
asia sinc month straumann fulli competit solut
compani start sell scanner product rang us market
sinc earli compani command dentalw scanner offer
lower end market
compani work strategi detect treat cari camera
recent set test portfolio innov materi
sale ebit straumann report result
cse sale also vara consensu
sale came underli y/i ahead
consensu estim underli sale growth rel expect
particular pleas emea north america perform
latin america asia/pacif line
clean gross margin came y/i compar basi due mix
chang versu cse adj ebit came margin
y/i busi profit leverag sale distribut cse
margin
figur varianc cs estim consensu
sfr million unless otherwis state
consensu varianc consensu
driven implant doubl digit growth gener half
group growth result restor doubl digit
growth biomateri acceler august
dynam increas belgium iberia russia sweden uk
socio-econom uncertainti itali off-set good growth
germani switzerland growth lift new
acquisit effect mainli clear correct implant
busi particularli blt main driver alongsid
dynam growth neodent non-premium segment
doubl digit growth averag growth owe
implant abut cadcam clear align
fastest grow region currenc tailwind dynam
expans china help strong perform korea
subsidiari grew doubl digit except japan
currenc weak notabl brazilian despit polit
econom challeng improv sale high price product
manag guid underli sale growth low teen
improv underli margin note past year first
charl martineau pm univers toronto guidanc compani typic proven conserv subsequ
upgrad throughout year
figur cs estim chang
sfr million unless otherwis state
sale
ebit
currenc market cap us share price ev/sal
sfr million unless otherwis state
tax adj ebit
chang work capit wc
chang asset
invest intang acquist
financi asset botiss etc
equiti valu per share sfr
oper work capit sale
capital-expenditure sale
sfr million unless otherwis state
sale growth local currenc
sale growth sfr
sale product
sfr million unless otherwis state
good sold
sale
gross invest fix asset
depreci
sale
gross fix asset
invest intang
amort acquisit relat intang
amort intang
amort intang
currenc gain loss
share result assocait
compani mention price
